Tetrahydrocannabivarin (THCV) Research Dashboard
Studies by Organ System
No data to display
Studies by Country of Researcher
No data to display
Top Conditions Related to THCV Studies
No data to display
Receptors Associated with THCV Studies
No data to display
There Is Clinical Evidence Using THCV for These Conditions:
Page Quick Links
Select New Cannabinoid
56 PRIMARY STUDIES | 96 TOTAL STUDIES
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management
Research and Clinical Practice Involving the Use of Cannabis Products, with Emphasis on Cannabidiol: A Narrative Review
Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips
Minor Cannabinoids as an Emerging Frontier for Pain Relief
Use of phytocanabinoids in animal models of Parkinson's disease: Systematic review
Select Minor Cannabinoids from Cannabis sativa Are Cannabimimetic and Antinociceptive in a Mouse Model of Chronic Neuropathic Pain
Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review
Case reports of identical twins with developmental and epileptic encephalopathy with STXBP1 gene mutations for whom different CBD supplementations were markedly effective
Effects of cannabinoids on resting state functional brain connectivity: A systematic review
Molecular pathway and structural mechanism of human oncochannel TRPV6 inhibition by the phytocannabinoid tetrahydrocannabivarin
Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway
Cross-substance primed and cue-induced craving among alcohol and cannabis co-users: An experimental psychopharmacology approach
Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes
A Systematic Review of Medical Cannabinoids Dosing in Human
Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice
The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson's Disease: A Systematic Literature Review of Pre-Clinical Studies
An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models
Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target
Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment
Specific Compositions of Cannabis sativa Compounds Have Cytotoxic Activity and Inhibit Motility and Colony Formation of Human Glioblastoma Cells In Vitro
Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis
Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats
The Cannabinoids Tetrahydrocannabinol, Cannabinol, Cannabidiol, Tetrahydrocannabivarin, and 11-nor-9-carboxy-∆9-THC in Hair
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice
Cannabinoids and Chronic Liver Diseases
High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain
Antioxidant and antimicrobial activity of two standardized extracts from a new Chinese accession of non-psychotropic Cannabis sativa L
Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath
Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes
Synthesis of the Major Mammalian Metabolites of THCV
Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes
Effects of non‐euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice
The current status of artisanal cannabis for the treatment of epilepsy in the United States
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile
Δ8-Tetrahydrocannabivarin Prevents Hepatic Ischaemia/Reperfusion Injury by Decreasing Oxidative Stress and Inflammatory Responses Through Cannabinoid CB2 Receptors
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception
The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo
Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study
Cannabivarin and Tetrahydrocannabivarin, Two New Constituents of Hashish
40 RELATED STUDIES | 96 TOTAL STUDIES
Editorial: Insights on cannabinoid translational science and medicine: the endocannabinoidome as a target for clinical practice
Pharmacokinetics of Orally Applied Cannabinoids and Medical Marijuana Extracts in Mouse Nervous Tissue and Plasma: Relevance for Pain Treatment
Cannabis Use and the Endocannabinoid System: A Clinical Perspective
Cannabis sativa Extract Induces Apoptosis in Human Pancreatic 3D Cancer Models: Importance of Major Antioxidant Molecules Present Therein
A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment
In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils
The Medicinal Natural Products of Cannabis sativa Linn.: A Review
Profiling Cannabinoid Contents and Expression Levels of Corresponding Biosynthetic Genes in Commercial Cannabis (Cannabis sativa L.) Cultivars
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations
Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug
Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users
Quantitation of Δ8-THC, Δ9-THC, Cannabidiol, and Ten Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS/MS
Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms
Development and Optimization of Supercritical Fluid Extraction Setup Leading to Quantification of 11 Cannabinoids Derived from Medicinal Cannabis
Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots
Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels
The Current and Potential Application of Medicinal Cannabis Products in Dentistry
Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
Biomarkers of Recent Cannabis Use in Blood, Oral Fluid and Breath
Detectability of cannabinoids in the serum samples of cannabis users: Indicators of recent cannabis use? A follow-up study
Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages
Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa
Cannabinoids and Cannabinoid Receptors: The Story so Far
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets
Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary
Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome
Future Aspects for Cannabinoids in Breast Cancer Therapy
Molecular Targets of the Phytocannabinoids-A Complex Picture
Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake
Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth In Vitro And In Vivo: Pro-apoptotic Effects And Underlying Mechanisms
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
Overview - Tetrahydrocannabivarin (THCV)
Description of Tetrahydrocannabivarin (THCV)
Δ-9-Tetrahydrocannabivarin (Δ-9-THCV) was discovered in 1969 (F. Merkus 1971).
THCV belongs to the THC group but produces significantly different effects than THC. This difference in effect is largely due to their different effects at CB1. THC is an agonist at CB1, while THCV is an antagonist at the same receptor and, as such, induces opposing effects. For instance, while THC can induce euphoria, THCV can produce dysphoria. THC increases appetite ("the munchies"), while THCV decreases the desire for food.
A lot of attention has been given to THCV of late due to the observation that it may be able to induce several therapeutic effects in patients challenged by metabolic syndrome, obesity, and diabetes. This is especially true in the context of the failed approach with Rimonabant (a full CB1 antagonist with a Ki of ~2nM) used extensively to induce weight loss but pulled from the EU market due to associated mood disorders, including suicidal ideations.
In one of the most recent clinical trials (2025), healthy obese adults in the early stages of developing metabolic syndrome received a once-daily dose of THCV and CBD-infused mucoadhesive strips. The resulting data revealed clinically significant weight loss and decreases in abdominal girth, systolic blood pressure, and total and LDL cholesterol (G. Smith 2025) thus confirming earlier pre-clinical trial results.
Δ(8) -THCV (is a synthetic analog of the plant cannabinoid Δ(9) -THCV.
Here we focus primarily on Δ-9-THCV.
Other Names:
Delta 9-TetrahydrocannabivarinTHCV, THC-V, Delta-9-Tetrahydrocannabivarin, Δ-9-Tetrahydrocannabivarin, plus numerous other supplier-based synonyms.
IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Molecular Formula: C19H26O2
Source–PubChem
Tetrahydrocannabivarin (THCV) Properties and Effects
Δ-9-THCV may induce the following properties and effects:
- Analgesia
- Inflammatory pain (reduction) (D. Bolognini et al., 2010)
- Paclitaxel-induced peripheral neuropathy (reduction) (A. Kavala et al., 2022)
- Anti-addictive (cannabis) (E. Galaj et al., 2019)
- Anti-addictive (opioids) (E. Galaj et al., 2019)
- Anti-diabetic
- Adiponectin (improved function of this natural hormone that helps to regulate glucose levels) (K. Jadoon et al., 2016)
- Insulin sensitivity (improved) (E. Wargent et al., 2013)
- Glucose levels (decrease plasma glucose concentrations) (K. Jadoon et al., 2016)
- Pancreatic beta-cell (improved function) (K. Jadoon et al., 2016)
- Anti-cancer (A. Neuberger et al., 2023)
- Anti-dyskinesia (Δ-9-THCV reduced L-DOPA-induced dyskinesia) (I. Espadas et al., 2020)
- Anti-epileptic (A. Hill et al., 2010)
- Anti-nausea (E. Rock et al., 2013)
- Anti-obesity (E. Wargent et al., 2013)
- Antioxidant (C. Garcia et al., 2011)
- Anti-psychotic (potentially beneficial effects via serotonin receptor site activation) (M. Cascio et al., 2015)
- Appetite-suppressant (A. Abioye et al., 2020)
- Dysphoric (full antagonists at CB1 have been shown to induce dysphoric effects-see SR-141716A) (R. Christensen et al., 2007; F. Akbas et al., 2009)
- Neuroprotective (C. Garcia et al., 2011)
- Antimicrobial (i.e., effective against MRSA)
Δ-8-THCV may:
- Anti-addictive (nicotine) (Z. Xi. et al., 2019)
Adverse Effects of THCV:
THCV is an antagonist at CB1, which has led some researchers to remain concerned about its possible dysphoric effects (especially when administered as a stand-alone).
Tetrahydrocannabivarin (THCV) Receptor Binding
The endocannabinoid system (ECS) and THCV:
- CB1 antagonist with a mean Ki of ~84nM using data from 5 trials (J. McPartland et al., 2015); in contrast, Rimonabant (aka SR-141716A) is a full CB1 antagonist with a Ki of ~2nM (M. Rinaldi-Carmona et al., 1994).
- THCV is an inhibitor of CB1 agonists (e.g., reduced THC-associated increases in heart rate, decrease in THC-associated psychoactivity) while increasing others, i.e., significantly increased memory intrusions
- CB2 agonist with a mean Ki of ~125nM using data from 3 trials (J. McPartland et al., 2015)
Endocannabinoidome (eCBome) and THCV:
- GPR-55 (Mixed results, THCV acted as an agonist/antagonist (E. Wargent et al., 2020)
- TRPV6 (potential inhibitor) (A. Neuberger et al., 2023)
- Serotonin receptor sites
- 5-HT1A (may act as a positive allosteric modulator) (M. Cascio et al., 2015)
Ki legend:
- Full/strong agonist Ki ~1-9nM
- Moderate agonist Ki ~10-99nM
- Weak agonist Ki ~100-999nM
- Very weak agonist Ki ~1,000-up nM
(The reader is reminded that a smaller Ki is associated with the strongest effects.)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
